Berkeley Capital Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.55M | Sell |
64,286
-31,356
| -33% | -$820K | 0.32% | 63 |
|
|
2026
Q1 | $2.69M | Buy |
95,642
+22,653
| +31% | +$603K | 0.62% | 26 |
|
|
2025
Q4 | $1.82M | Buy |
72,989
+581
| +0.8% | +$14.7K | 0.43% | 44 |
|
|
2025
Q3 | $1.84M | Sell |
72,408
-3,404
| -4% | -$84K | 0.44% | 41 |
|
|
2025
Q2 | $1.84M | Buy |
75,812
+3,768
| +5% | +$87.9K | 0.47% | 40 |
|
|
2025
Q1 | $1.83M | Buy |
72,044
+2,854
| +4% | +$74.7K | 0.5% | 38 |
|
|
2024
Q4 | $1.84M | Buy |
69,190
+1,531
| +2% | +$41.5K | 0.51% | 32 |
|
|
2024
Q3 | $1.96M | Buy |
67,659
+2,169
| +3% | +$63.3K | 0.56% | 31 |
|
|
2024
Q2 | $1.83M | Buy |
65,490
+1,032
| +2% | +$28.4K | 0.55% | 33 |
|
|
2024
Q1 | $1.79M | Buy |
64,458
+33,075
| +105% | +$918K | 0.55% | 33 |
|
|
2023
Q4 | $904K | Sell |
31,383
-393
| -1% | -$11.9K | 0.3% | 71 |
|
|
2023
Q3 | $1.05M | Sell |
31,776
-340
| -1% | -$12K | 0.38% | 55 |
|
|
2023
Q2 | $1.18M | Buy |
32,116
+18
| +0.1% | +$701 | 0.42% | 49 |
|
|
2023
Q1 | $1.31M | Sell |
32,098
-10,651
| -25% | -$460K | 0.49% | 40 |
|
|
2022
Q4 | $2.19M | Sell |
42,749
-445
| -1% | -$21.3K | 0.85% | 20 |
|
|
2022
Q3 | $1.89M | Buy |
43,194
+442
| +1% | +$21.5K | 0.82% | 17 |
|
|
2022
Q2 | $2.24M | Buy |
42,752
+605
| +1% | +$30.8K | 0.92% | 14 |
|
|
2022
Q1 | $2.18M | Buy |
42,147
+183
| +0.4% | +$9.49K | 0.87% | 17 |
|
|
2021
Q4 | $2.48M | Sell |
41,964
-3,100
| -7% | -$154K | 1.02% | 15 |
|
|
2021
Q3 | $1.94M | Sell |
45,064
-701
| -2% | -$31.1K | 0.89% | 16 |
|
|
2021
Q2 | $1.79M | Sell |
45,765
-190
| -0.4% | -$7.39K | 0.8% | 20 |
|
|
2021
Q1 | $1.67M | Buy |
45,955
+219
| +0.5% | +$7.78K | 0.8% | 19 |
|
|
2020
Q4 | $1.68M | Sell |
45,736
-4,977
| -10% | -$183K | 0.86% | 16 |
|
|
2020
Q3 | $1.77M | Sell |
50,713
-6,292
| -11% | -$221K | 1.08% | 14 |
|
|
2020
Q2 | $1.77M | Sell |
57,005
-7,154
| -11% | -$243K | 1.09% | 13 |
|
|
2020
Q1 | $1.99M | Buy |
64,159
+25,392
| +65% | +$865K | 1.35% | 11 |
|
|
2019
Q4 | $1.44M | Sell |
38,767
-2,186
| -5% | -$77.9K | 0.74% | 23 |
|
|
2019
Q3 | $1.4M | Sell |
40,953
-816
| -2% | -$29.7K | 0.74% | 22 |
|
|
2019
Q2 | $1.72M | Buy |
41,769
+20
| +0% | +$794 | 0.8% | 18 |
|
|
2019
Q1 | $1.68M | Buy |
41,749
+2,048
| +5% | +$82K | 0.83% | 17 |
|
|
2018
Q4 | $1.64M | Sell |
39,701
-1,447
| -4% | -$60.1K | 0.91% | 18 |
|
|
2018
Q3 | $1.72M | Sell |
41,148
-8,007
| -16% | -$308K | 0.97% | 18 |
|
|
2018
Q2 | $1.69M | Sell |
49,155
-338
| -0.7% | -$11.6K | 0.99% | 18 |
|
|
2018
Q1 | $1.67M | Buy |
49,493
+13,277
| +37% | +$456K | 0.96% | 17 |
|
|
2017
Q4 | $1.25M | Buy |
36,216
+912
| +3% | +$31.1K | 0.82% | 25 |
|
|
2017
Q3 | $1.2M | Sell |
35,304
-3,530
| -9% | -$113K | 0.8% | 27 |
|
|
2017
Q2 | $1.24M | Buy |
38,834
+5,547
| +17% | +$175K | 0.84% | 22 |
|
|
2017
Q1 | $1.08M | Sell |
33,287
-1,216
| -4% | -$38.3K | 0.73% | 28 |
|
|
2016
Q4 | $1.06M | Buy |
34,503
+347
| +1% | +$10.6K | 0.77% | 27 |
|
|
2016
Q3 | $1.1M | Sell |
34,156
-1,457
| -4% | -$48.7K | 0.78% | 25 |
|
|
2016
Q2 | $1.19M | Sell |
35,613
-10,531
| -23% | -$336K | 0.84% | 24 |
|
|
2016
Q1 | $1.3M | Buy |
46,144
+13,211
| +40% | +$377K | 0.94% | 24 |
|
|
2015
Q4 | $1.01M | Buy |
+32,933
| New | +$1.04M | 0.82% | 27 |
|
Other funds holding PFE
Berkeley Capital Partners's PFE Position: Q2 2026 in Review
Berkeley Capital Partners reduced its Pfizer (PFE) stake by 33% in Q2 2026, selling an estimated $820K and leaving 64,286 shares worth $1.55M. The position accounts for 0.32% of the portfolio, ranked #63.
Berkeley Capital Partners first reported a position in PFE in Q4 2015 and has held it in 43 quarters since. The position peaked at $2.69M in Q1 2026. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Berkeley Capital Partners held 64,286 shares of Pfizer worth $1.55M as of Q2 2026.
- Berkeley Capital Partners sold 31,356 Pfizer shares in Q2 2026, an estimated $820K.
- Pfizer made up 0.32% of Berkeley Capital Partners's portfolio in Q2 2026, its #63 holding.
- Berkeley Capital Partners first reported a position in Pfizer in Q4 2015 and has held it in 43 quarters since.
- Berkeley Capital Partners's Pfizer position peaked at $2.69M in Q1 2026.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Berkeley Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.